Skip to main
TRAXV

First Tracks Biotherapeutics Inc (TRAXV)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy TRAXV Stock

About First Tracks Biotherapeutics Inc (TRAXV)

The full company name is First Tracks Biotherapeutics Inc.
Market cap
Yesterday's volume651
Revenue (TTM)
Avg. daily volume651
EBITDA (TTM)
Open$20
Price / earnings ratio
Yesterday's range$19 - $20
Debt / equity
52 week range$19 - $20
5 year debt / equity
Beta (LTM)
Interest coverage
Dividend & yield$0.00 (0.00%)
Current ratio
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

The 52-week high for TRAXV stock is $20. The current TRAXV stock price $undefined is 100.00% below its 52-week high

The 52-week low for TRAXV stock is $19. The current TRAXV stock price $undefined has increased 100.00% from its 52-week low

No, the TRAXV stock does not pay dividends to its shareholders

How to buy TRAXV stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in TRAXV stock

    Navigate to the Explore page. Then, type TRAXV into the search bar. When you see TRAXV stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased TRAXV stock in your portfolio alongside the rest of your stocks, ETFs, crypto, bonds, options, and your high-yield cash account––all in one place on Public.

Buy TRAXV Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.